Nutriband (NTRB) Competitors

$3.59 +0.09 (+2.57%)

Closing price 04:00 PM Eastern

Extended Trading

$3.61 +0.02 (+0.50%)

As of 07:55 PM Eastern

NTRB vs. HYPR, SMTI, PDEX, MBOT, and STIM

Should you buy Nutriband stock or one of its competitors? MarketBeat compares Nutriband with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nutriband include Hyperfine (HYPR), Sanara MedTech (SMTI), Pro-Dex (PDEX), Microbot Medical (MBOT), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.

How does Nutriband compare to Hyperfine?

Nutriband (NASDAQ:NTRB) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Nutriband has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Hyperfine has a consensus target price of $1.59, suggesting a potential downside of 0.78%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts plainly believe Hyperfine is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Hyperfine has a net margin of -226.88% compared to Nutriband's net margin of -403.98%. Hyperfine's return on equity of -98.83% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Hyperfine	-226.88%	-98.83%	-67.09%

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nutriband has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	21.43	-$8.23M	-$2.60	N/A
Hyperfine	$11.40M	13.75	-$35.57M	-$0.44	N/A

In the previous week, Hyperfine had 9 more articles in the media than Nutriband. MarketBeat recorded 10 mentions for Hyperfine and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Hyperfine's score of 0.38 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
Hyperfine	Neutral

Summary

Hyperfine beats Nutriband on 9 of the 16 factors compared between the two stocks.

How does Nutriband compare to Sanara MedTech?

Nutriband (NASDAQ:NTRB) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Nutriband has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Sanara MedTech has a consensus price target of $34.00, suggesting a potential upside of 57.12%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sanara MedTech	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sanara MedTech has a net margin of -31.23% compared to Nutriband's net margin of -403.98%. Sanara MedTech's return on equity of -3.19% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Sanara MedTech	-31.23%	-3.19%	-0.56%

19.7% of Nutriband shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nutriband has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	21.43	-$8.23M	-$2.60	N/A
Sanara MedTech	$103.12M	1.92	-$37.56M	-$3.77	N/A

In the previous week, Sanara MedTech had 10 more articles in the media than Nutriband. MarketBeat recorded 11 mentions for Sanara MedTech and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Sanara MedTech's score of 0.49 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
Sanara MedTech	Neutral

Summary

Nutriband and Sanara MedTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Nutriband compare to Pro-Dex?

Nutriband (NASDAQ:NTRB) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Nutriband has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

In the previous week, Pro-Dex had 9 more articles in the media than Nutriband. MarketBeat recorded 10 mentions for Pro-Dex and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Pro-Dex's score of 1.28 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
Pro-Dex	Positive

19.7% of Nutriband shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pro-Dex has a consensus price target of $70.00, suggesting a potential upside of 19.35%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts plainly believe Pro-Dex is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Pro-Dex has a net margin of 16.08% compared to Nutriband's net margin of -403.98%. Pro-Dex's return on equity of 22.78% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Pro-Dex	16.08%	22.78%	14.30%

Pro-Dex has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	21.43	-$8.23M	-$2.60	N/A
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.20

Summary

Pro-Dex beats Nutriband on 11 of the 16 factors compared between the two stocks.

How does Nutriband compare to Microbot Medical?

Nutriband (NASDAQ:NTRB) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Nutriband has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Microbot Medical had 4 more articles in the media than Nutriband. MarketBeat recorded 5 mentions for Microbot Medical and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Microbot Medical's score of 1.29 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
Microbot Medical	Positive

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Microbot Medical has a consensus price target of $7.50, suggesting a potential upside of 305.41%. Given Microbot Medical's stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Microbot Medical has a net margin of 0.00% compared to Nutriband's net margin of -403.98%. Microbot Medical's return on equity of -22.91% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Microbot Medical	N/A	-22.91%	-21.70%

Nutriband has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	21.43	-$8.23M	-$2.60	N/A
Microbot Medical	N/A	N/A	-$13.14M	-$0.29	N/A

Summary

Microbot Medical beats Nutriband on 9 of the 16 factors compared between the two stocks.

How does Nutriband compare to Neuronetics?

Nutriband (NASDAQ:NTRB) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Neuronetics has a consensus target price of $3.00, suggesting a potential upside of 130.77%. Given Neuronetics' stronger consensus rating and higher probable upside, analysts clearly believe Neuronetics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuronetics has a net margin of -24.48% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Neuronetics	-24.48%	-139.83%	-27.13%

19.7% of Nutriband shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nutriband has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Nutriband has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	21.43	-$8.23M	-$2.60	N/A
Neuronetics	$149.16M	0.61	-$39M	-$0.54	N/A

In the previous week, Neuronetics had 3 more articles in the media than Nutriband. MarketBeat recorded 4 mentions for Neuronetics and 1 mentions for Nutriband. Neuronetics' average media sentiment score of 1.93 beat Nutriband's score of 1.87 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nutriband	Very Positive
Neuronetics	Very Positive

Summary

Neuronetics beats Nutriband on 10 of the 16 factors compared between the two stocks.

Get Nutriband News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRB vs. The Competition

Export

Metric	Nutriband	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.55M	$3.06B	$6.34B	$12.38B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-1.38	18.70	20.90	25.61
Price / Sales	21.43	272.77	549.93	78.79
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	6.53	4.42	9.93	6.96
Net Income	-$8.23M	$72.19M	$3.55B	$333.52M
7 Day Performance	-5.28%	-0.62%	-0.33%	0.45%
1 Month Performance	-11.58%	0.22%	1.34%	4.06%
1 Year Performance	-36.35%	46.24%	41.10%	36.24%

Nutriband Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRB Nutriband	0.6123 of 5 stars	$3.59 +2.6%	N/A	-38.9%	$42.55M	$2.04M	N/A	10	Positive News
HYPR Hyperfine	2.1221 of 5 stars	$1.71 -5.5%	$1.59 -7.2%	+127.2%	$177.30M	$11.40M	N/A	190	Earnings Report Analyst Forecast
SMTI Sanara MedTech	2.4621 of 5 stars	$19.62 +3.3%	$34.00 +73.3%	-39.9%	$174.04M	$103.12M	N/A	60	News Coverage Analyst Downgrade Gap Up
PDEX Pro-Dex	2.4958 of 5 stars	$56.00 +9.3%	$56.00	+35.2%	$163.57M	$66.59M	15.47	140	News Coverage Positive News Analyst Forecast Analyst Revision Gap Down
MBOT Microbot Medical	2.4588 of 5 stars	$2.10 -0.5%	$7.50 +257.1%	-8.8%	$141.70M	N/A	N/A	20	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRB) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutriband (NTRB) Competitors

NTRB vs. HYPR, SMTI, PDEX, MBOT, and STIM

How does Nutriband compare to Hyperfine?

Summary

How does Nutriband compare to Sanara MedTech?

Summary

How does Nutriband compare to Pro-Dex?

Summary

How does Nutriband compare to Microbot Medical?

Summary

How does Nutriband compare to Neuronetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutriband (NTRB) Competitors

NTRB vs. HYPR, SMTI, PDEX, MBOT, and STIM

How does Nutriband compare to Hyperfine?

Which has more risk & volatility, NTRB or HYPR?

Do analysts rate NTRB or HYPR?

Is NTRB or HYPR more profitable?

Do insiders and institutionals hold more shares of NTRB or HYPR?

Which has better earnings & valuation, NTRB or HYPR?

Does the media refer more to NTRB or HYPR?

Summary

How does Nutriband compare to Sanara MedTech?

Which has more volatility & risk, NTRB or SMTI?

Do analysts rate NTRB or SMTI?

Is NTRB or SMTI more profitable?

Do insiders & institutionals have more ownership in NTRB or SMTI?

Which has better earnings & valuation, NTRB or SMTI?

Does the media prefer NTRB or SMTI?

Summary

How does Nutriband compare to Pro-Dex?

Which has more volatility & risk, NTRB or PDEX?

Does the media prefer NTRB or PDEX?

Do insiders & institutionals have more ownership in NTRB or PDEX?

Do analysts rate NTRB or PDEX?

Is NTRB or PDEX more profitable?

Which has better earnings & valuation, NTRB or PDEX?

Summary

How does Nutriband compare to Microbot Medical?

Which has more risk and volatility, NTRB or MBOT?

Does the media refer more to NTRB or MBOT?

Do institutionals & insiders hold more shares of NTRB or MBOT?

Do analysts prefer NTRB or MBOT?

Is NTRB or MBOT more profitable?

Which has stronger valuation & earnings, NTRB or MBOT?

Summary

How does Nutriband compare to Neuronetics?

Do analysts prefer NTRB or STIM?

Is NTRB or STIM more profitable?

Do institutionals and insiders have more ownership in NTRB or STIM?

Which has more risk & volatility, NTRB or STIM?

Which has preferable valuation & earnings, NTRB or STIM?

Does the media prefer NTRB or STIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools